Quest for the best
- 1 October 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (10) , 838-841
- https://doi.org/10.1038/nrd1203
Abstract
By combining innovative science with years of massive investment, drug makers seek to turn newly discovered chemicals into revolutionary blockbuster drugs that generate billions of dollars in revenue. So every year, they collectively spend tens of billions of dollars on the high-risk pursuit of the next Prozac or Viagra. But should they? This article analyses key themes around differentiation that we have found to be common among blockbusters, and examines the implications for creating future billion-dollar drugs.Keywords
This publication has 5 references indexed in Scilit:
- Too many drugs? The clinical and economic value of incremental innovationsPublished by Emerald Publishing ,2004
- Strategic trends in the drug industryDrug Discovery Today, 2003
- Value of novelty?Nature Reviews Drug Discovery, 2002
- Discovery, innovation and the cyclical nature of the pharmaceutical businessDrug Discovery Today, 2002
- Innovation in the pharmaceutical industryJournal of the Royal Society of Medicine, 2000